Can I Take Quercetin With Alprostadil (Caverject/MUSE)?

How Alprostadil Is Metabolized (and Why CYP3A4 Matters Less Than You Think)

Alprostadil (prostaglandin E1) follows a metabolic route that is distinct from most oral medications. After intracavernosal injection or intraurethral insertion, the drug acts locally in penile vascular smooth muscle and is then rapidly cleared during a single pass through the pulmonary circulation [1]. The FDA-approved Caverject prescribing information states that approximately 80% of circulating alprostadil is enzymatically degraded in the lungs by 15-hydroxyprostaglandin dehydrogenase and subsequent beta- and omega-oxidation [2].

Why CYP3A4 Is Not the Primary Concern

Quercetin's reputation as a drug interaction risk stems largely from its ability to inhibit cytochrome P450 3A4 (CYP3A4) in vitro [3]. A 2002 study in The Journal of Pharmacology and Experimental Therapeutics demonstrated that quercetin inhibited CYP3A4-mediated midazolam metabolism with an IC50 of approximately 1.97 µM in human liver microsomes [3]. That finding is real. The problem is applying it to alprostadil.

Because alprostadil does not depend on CYP3A4 (or any hepatic cytochrome P450 isoenzyme) for its primary clearance, blocking that enzyme has no meaningful effect on alprostadil's plasma concentration or half-life. The drug's plasma half-life is already very short, roughly 30 seconds to 10 minutes depending on formulation, and clearance occurs almost entirely through pulmonary prostaglandin dehydrogenase [2].

What the Interaction Databases Say

Neither the Natural Medicines Comprehensive Database nor the FDA's adverse event reporting system (FAERS) lists a formal interaction between quercetin and alprostadil. The absence of a listed interaction aligns with the pharmacokinetic logic: if the drug does not travel through the pathway the supplement inhibits, a kinetic interaction is not expected.

The Real Consideration: Additive Vasodilation

The interaction that does deserve attention is pharmacodynamic, not pharmacokinetic. Both alprostadil and quercetin promote vasodilation through separate mechanisms, and the combined effect on blood pressure is the practical concern for patients.

How Alprostadil Lowers Vascular Resistance

Alprostadil relaxes vascular smooth muscle by stimulating adenylate cyclase, increasing intracellular cyclic AMP (cAMP), and activating protein kinase A [1]. This is the mechanism that produces its therapeutic erection, but it also causes systemic effects at higher doses: the Caverject label lists dizziness (1 to 4%) and hypotension (<1%) as reported adverse events [2].

How Quercetin Affects Blood Pressure

A 2016 meta-analysis of seven randomized controlled trials (N = 587) published in Nutrition Reviews found that quercetin supplementation at doses of 500 mg/day or higher reduced systolic blood pressure by a mean of 4.45 mmHg (95% CI: −7.25 to −1.64) and diastolic blood pressure by 2.98 mmHg (95% CI: −4.58 to −1.37) [4]. The mechanism involves nitric oxide (NO) pathway enhancement and inhibition of angiotensin-converting enzyme (ACE) activity [5].

Combined Vasodilatory Load

When a patient injects 10 to 20 mcg of alprostadil and is also taking 500 to 1,000 mg of quercetin daily, the vasodilatory effects may overlap. This does not mean the combination is dangerous for most people. It means that the patient who already runs a low resting blood pressure (systolic <110 mmHg) should be more cautious, and anyone using alprostadil should check seated blood pressure before injection on days they take quercetin.

No published clinical trial has tested this specific combination. The guidance here is extrapolated from the known hemodynamic profiles of each compound individually.

Quercetin's Antiplatelet Effects and Alprostadil

Quercetin also inhibits platelet aggregation. A 2016 study in Thrombosis Research showed that quercetin at physiologically achievable concentrations inhibited collagen-induced platelet aggregation by 48% and thrombin-induced aggregation by 35% in human whole blood [6]. Alprostadil itself inhibits platelet aggregation through its cAMP-elevating mechanism [1].

Clinical Relevance for Injection-Site Bruising

Patients using intracavernosal alprostadil (Caverject) already experience penile hematoma or ecchymosis at rates of 3 to 5% per the product label [2]. The additive antiplatelet activity from quercetin could modestly increase bruising risk at the injection site. This is a low-grade concern, not a safety signal. Patients should watch for worsening injection-site bruising if they start quercetin and report any unusual hematoma to their prescriber.

For intraurethral alprostadil (MUSE), the injection-site bruising concern does not apply, though minor urethral bleeding is reported in approximately 5% of MUSE users [7].

Who Should Be Most Cautious

Not all patients taking alprostadil carry the same risk profile when adding quercetin. Certain subgroups should approach the combination with more attention.

Patients on Concurrent Antihypertensives

A patient already taking amlodipine 5 mg, lisinopril 10 mg, or another antihypertensive adds a third vasodilatory layer with quercetin and a fourth with alprostadil. The Endocrine Society's 2018 clinical practice guideline on testosterone therapy (which often overlaps with alprostadil prescribing populations) notes that hypotension risk increases with each added vasodilator [8]. These patients should measure blood pressure before alprostadil injection.

Patients Taking Anticoagulants or Antiplatelets

If a patient takes warfarin, aspirin, or clopidogrel alongside alprostadil and quercetin, the triple antiplatelet or anticoagulant overlap becomes meaningful. The prescriber should review bleeding risk. A 2012 case report in Phytotherapy Research described elevated INR in a patient on warfarin after starting quercetin 1,000 mg daily [9].

Patients With Hepatic Impairment

While alprostadil itself does not rely on hepatic metabolism, patients with liver disease may have altered clearance of quercetin metabolites. Quercetin undergoes extensive phase II conjugation (glucuronidation and sulfation) in the liver and intestine [10]. Hepatic impairment slows this clearance, potentially increasing free quercetin concentrations and amplifying its pharmacodynamic effects.

Practical Dosing and Timing Guidance

Because the interaction is pharmacodynamic (additive vasodilation) rather than pharmacokinetic (enzyme competition), traditional "dose separation" strategies are less critical here than they are with drugs that compete for the same metabolic enzyme. Practical spacing can reduce the overlap of peak effects.

Suggested Timing Approach

Quercetin reaches peak plasma concentration approximately 1 to 2 hours after oral ingestion, with a terminal half-life of roughly 11 to 28 hours depending on formulation [10]. Alprostadil's onset of action is 5 to 20 minutes after injection, with clinical effect lasting 30 to 60 minutes [2].

Taking quercetin in the morning and using alprostadil in the evening (or vice versa) spaces the two peak-effect windows apart by 8 or more hours. This is a reasonable strategy for patients who report dizziness or lightheadedness after alprostadil injection while taking quercetin. It is not a strict requirement.

Monitoring Protocol

1. Measure seated blood pressure before the first alprostadil injection after starting quercetin. If systolic BP is below 100 mmHg, defer the injection and consult your prescriber.
2. Watch for new or worsened injection-site bruising over the first four to six uses.
3. Report dizziness, syncope, or prolonged erection (priapism) immediately. Priapism is an alprostadil-specific risk (incidence ~1% per Caverject label) and is not expected to increase with quercetin, but any change in erection duration after adding a new supplement warrants reporting [2].

What To Do if You Are Already Taking Both

Many patients discover supplement-drug interaction questions only after they have been taking both compounds for weeks or months. If you are already using quercetin alongside alprostadil without adverse effects, that is itself useful clinical data. There is no need to stop quercetin abruptly.

If You Are Tolerating Both Well

Continue the current regimen. No dose adjustment is needed. Mention the combination at your next prescriber visit so it can be documented in your medication list.

If You Notice New Side Effects

New dizziness after alprostadil injection, worsened bruising, or lightheadedness on standing may relate to the additive vasodilatory and antiplatelet effects. Reduce quercetin to 250 mg per day or temporarily discontinue it, then re-challenge at a lower dose after discussing with your prescriber.

Quercetin Dose Ranges and Evidence for Common Uses

Patients taking quercetin alongside alprostadil often use the flavonoid for one of several reasons: seasonal allergy symptom control (quercetin stabilizes mast cell histamine release), cardiovascular antioxidant support, or chronic prostatitis symptom management.

Allergy and Antihistamine Use

In vitro studies show quercetin inhibits mast cell degranulation and histamine release at concentrations achievable with oral supplementation of 500 to 1,000 mg daily [11]. A randomized trial in 2013 (N = 60) published in the International Archives of Allergy and Immunology reported a significant reduction in allergic rhinitis symptom scores with quercetin 200 mg twice daily over eight weeks [12]. At these doses, the blood-pressure effect described above remains modest.

Chronic Prostatitis

A 1999 randomized, double-blind, placebo-controlled trial (N = 30) published in Urology found that quercetin 500 mg twice daily for four weeks significantly improved NIH Chronic Prostatitis Symptom Index scores compared to placebo (p = 0.003) [13]. Patients using alprostadil for erectile dysfunction who also have chronic prostatitis may reasonably take quercetin for both conditions. The overlap is common in urology practice.

The Bottom Line on This Combination

The quercetin-alprostadil pairing carries no established pharmacokinetic interaction. Alprostadil's rapid pulmonary metabolism sidesteps the CYP3A4 pathway that quercetin inhibits. The relevant concern is a modest pharmacodynamic overlap: additive vasodilation and additive antiplatelet activity. For the majority of patients, this combination is manageable with blood pressure awareness and injection-site monitoring. Patients on multiple antihypertensives or anticoagulants should flag the combination to their prescriber before continuing.

Measure seated blood pressure before your next alprostadil injection if you have recently started quercetin at 500 mg/day or above.